Can you create a visual schematic of the pathogenic sequence of sarcoidosis?

Visual Schematic of Sarcoidosis Pathogenic Sequence

Sarcoidosis develops through a sequential cascade beginning with antigen exposure in genetically susceptible individuals, progressing through macrophage activation and T-cell mediated immunity, culminating in characteristic non-caseating granuloma formation with potential progression to fibrosis. 1

Pathogenic Sequence Flow

Stage 1: Predisposition & Trigger

• Genetic susceptibility provides the foundational risk through functional polymorphisms 2
• Antigen exposure initiates the cascade—putative triggers include:
  • Mycobacterial antigens (mKatG, ESAT-6)
  • Cutibacterium acnes (formerly Propionibacterium acnes) 2, 3
  • Occupational/environmental exposures 4
  • Possibly self-antigens in some cases 5

Stage 2: Initial Immune Activation

• Alveolar macrophage activation occurs first 2
• Macrophages process and present antigens via MHC molecules
• Toll-like receptor signaling becomes dysregulated 5
• Enhanced local expression of Th1 cytokines begins 5

Stage 3: T-Cell Immunity Development

• CD4+ T-cell recruitment to sites of inflammation 2
• Oligoclonal T-cell expansion indicating chronic antigenic stimulation 5
• Th1/Th17.1 immune skewing drives inflammatory response 6
• Dysfunctional regulatory T-cell responses fail to suppress inflammation 5
• Elevated CD4:CD8 ratio in bronchoalveolar lavage fluid 1

Stage 4: Granuloma Formation (Hallmark Lesion)

Microscopic architecture 1:

• Central core: Compact aggregates of epithelioid histiocytes and multinucleated giant cells
• Outer layer: Loosely organized T lymphocytes with interposed dendritic cells
• Peripheral zone: Isolated B lymphocyte collections in some cases
• Key feature: Non-caseating (no extensive necrosis) 1

Anatomic distribution pattern 1:

• Perilymphatic location: Around bronchovascular bundles
• Along interlobular septa containing pulmonary veins
• Near visceral pleura
• Sparse surrounding lymphocytic infiltrate 1

Stage 5: Granuloma Evolution & Complications

Two potential pathways:

Pathway A - Resolution:

• Spontaneous granuloma disappearance (common in Löfgren's syndrome) 1
• Treatment-induced resolution
• Nodular hyalinized fibrosis with scattered multinucleated giant cells may remain 1

Pathway B - Progression to Fibrosis 1, 3:

• Fibrosis begins at granuloma periphery
• Progressive extension centrally into granuloma
• Calcification may occur
• Upper lobe scarring and contraction in chronic disease 3
• Cystic changes and occasional honeycombing 3

Stage 6: Vascular Involvement (Parallel Process)

• Granulomatous angiitis with vascular wall invasion 1, 3
• Microangiopathy: Endothelial injury with basement membrane multilamellation 3
• Affects multiple organs (heart, lung, eye, skin)

Molecular Mechanisms Driving Pathogenesis

Key signaling pathways 6:

• JAK-STAT pathway aberrations promote inflammation
• mTOR-driven metabolic shifts in immune cells
• Cytokine/chemokine circuits centered on granulomas maintain chronic inflammation
• Effector T-cell exhaustion in chronic disease

Systemic Manifestations Pattern

Multi-organ involvement sequence 1:

• Thoracic (90%): Bilateral hilar adenopathy, perilymphatic nodules
• Extrathoracic spread: Lymph nodes, skin, eyes, heart, liver, spleen, bones, nervous system
• Metabolic derangements: Abnormal vitamin D metabolism (elevated 1,25-dihydroxyvitamin D), hypercalcemia/hypercalciuria 1

Clinical Pitfalls

Critical distinction: The pathogenetic correlation between granulomas and microangiopathy remains unresolved 3—both processes occur but their mechanistic relationship is unclear.

Diagnostic challenge: No single causative agent exists; multiple triggers (microbes, microbial products, inorganic substances) may induce similar pathogenetic mechanisms leading to the clinical syndrome called sarcoidosis 2, 5.